2026-09-19T19:51:39Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1534652024-02-09T03:34:06Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022
Irvine, Darrell J.
Wittrup, K. Dane
Agarwal, Yash
Massachusetts Institute of Technology. Department of Biological Engineering
2024-02-08T15:11:19Z
2024-02-08T15:11:19Z
2022-05
2024-02-02T20:56:19.076Z
https://hdl.handle.net/1721.1/153465
https://orcid.org/0000-0001-7785-7828
Cancer immunotherapy provides a promising new alternative to traditional cancer treatment modalities such as chemotherapy and radiation. However, even the most effective therapies only show benefit in a subset of patients when used alone and so, combination therapy may be critical to maximizing anti-tumor responses in the clinic. Inflammatory cytokines such as interleukins-2, 12 and 15 promote potent anti-tumor immunity, but systemically administered cytokines are also highly toxic.
In this thesis, we engineered cytokines with a peptide tag containing multiple phosphoserine (pSer) residues, through in-cell phosphorylation during recombinant expression. Cytokines with pSer tags bind tightly to the common vaccine adjuvant aluminum hydroxide (alum) via ligand exchange. Intratumoral injection of pSer-cytokine-loaded alum led to prolonged retention of the proteins in tumors (>weeks) with minimal side effects. A single dose of alum-tethered interleukin-12 (IL-12) induced significant interferon-γ-mediated T-cell and NK-cell activity in tumors, increased tumor-antigen accumulation in draining lymph nodes, and elicited robust tumor-specific T cell priming. Intratumoral alum/cytokine therapy enhanced responses to checkpoint blockade, promoting cures in distinct poorly immunogenic syngeneic tumors while eliciting control over distant, untreated lesions and metastases. Thus, intratumoral treatment with alum-anchored cytokines presents a safe, tumor-agnostic approach to improve local and systemic anti-cancer immunity.
This thesis also contains abundant discussion about the potential disadvantages of persistently-retained IL-12 along with solutions to circumvent the obstacles while maintaining the high therapeutic-index benefits seen with local delivery of alum-bound cytokines. Overall, our work presents strong proof-of-concept for alum as a powerful delivery vehicle for cancer immunotherapy and further work could help unlock the true potential for precise spatiotemporal control after local drug delivery.
Ph.D.
Massachusetts Institute of Technology
In Copyright - Educational Use Permitted
Copyright MIT
http://rightsstatements.org/page/InC-EDU/1.0/
A materials-based approach for localized delivery of cancer immunotherapy
Thesis
application/pdf
Doctoral
Doctor of Philosophy
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="88fbdf76-eab2-4e51-98e3-3ce59f91c11c">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Title>A materials-based approach for localized delivery of cancer immunotherapy</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2022-05</PublicationDate>
<Authors>
<Author>
<DisplayName>Agarwal, Yash</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://rightsstatements.org/page/InC-EDU/1.0/</License>
<Abstract>Cancer immunotherapy provides a promising new alternative to traditional cancer treatment modalities such as chemotherapy and radiation. However, even the most effective therapies only show benefit in a subset of patients when used alone and so, combination therapy may be critical to maximizing anti-tumor responses in the clinic. Inflammatory cytokines such as interleukins-2, 12 and 15 promote potent anti-tumor immunity, but systemically administered cytokines are also highly toxic.
In this thesis, we engineered cytokines with a peptide tag containing multiple phosphoserine (pSer) residues, through in-cell phosphorylation during recombinant expression. Cytokines with pSer tags bind tightly to the common vaccine adjuvant aluminum hydroxide (alum) via ligand exchange. Intratumoral injection of pSer-cytokine-loaded alum led to prolonged retention of the proteins in tumors (>weeks) with minimal side effects. A single dose of alum-tethered interleukin-12 (IL-12) induced significant interferon-γ-mediated T-cell and NK-cell activity in tumors, increased tumor-antigen accumulation in draining lymph nodes, and elicited robust tumor-specific T cell priming. Intratumoral alum/cytokine therapy enhanced responses to checkpoint blockade, promoting cures in distinct poorly immunogenic syngeneic tumors while eliciting control over distant, untreated lesions and metastases. Thus, intratumoral treatment with alum-anchored cytokines presents a safe, tumor-agnostic approach to improve local and systemic anti-cancer immunity.
This thesis also contains abundant discussion about the potential disadvantages of persistently-retained IL-12 along with solutions to circumvent the obstacles while maintaining the high therapeutic-index benefits seen with local delivery of alum-bound cytokines. Overall, our work presents strong proof-of-concept for alum as a powerful delivery vehicle for cancer immunotherapy and further work could help unlock the true potential for precise spatiotemporal control after local drug delivery.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>